Quick Answer
PROVECTUS BIOPHARMACEUTICALS, INC. reported Revenue (ASC 606) of $336.1 thousand for fiscal year 2025.
PROVECTUS BIOPHARMACEUTICALS, INC. Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2025 | $336.1K | -45.5% |
| 2024 | $617.1K | +10.7% |
| 2023 | $557.7K | -43.6% |
| 2022 | $989.0K | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| June 30, 2025 | $57.5K | -77.5% | -79.4% |
| March 31, 2025 | $278.6K | +17.0% | +153.9% |
| September 30, 2024 | $109.7K | +57.4% | -57.0% |
| June 30, 2024 | $255.0K | +57.6% | +7.1% |
| March 31, 2024 | $238.1K | +16.1% | +241.4% |
| September 30, 2023 | $69.7K | -77.9% | -56.9% |
| June 30, 2023 | $161.8K | -49.7% | -21.1% |
| March 31, 2023 | $205.0K | +9.3% | -34.9% |
- PROVECTUS BIOPHARMACEUTICALS, INC. showed a decrease of -45.5% in Revenue (ASC 606) compared to the prior fiscal year.
- Over the 2022–2025 period, PROVECTUS BIOPHARMACEUTICALS, INC.’s revenue (asc 606) has declined by 66.0% (from $989.0 thousand to $336.1 thousand).
- The most recent figure is from PROVECTUS BIOPHARMACEUTICALS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: